Show simple item record

dc.contributor.authorPujades-Rodríguez, Mar*
dc.contributor.authorSchramm, Birgit*
dc.contributor.authorSom, Leakena*
dc.contributor.authorNerrienet, Eric*
dc.contributor.authorNarom, Prak*
dc.contributor.authorChanchhaya, Ngeth*
dc.contributor.authorFerradini, Laurent*
dc.contributor.authorBalkan, Suna*
dc.date.accessioned2011-01-25T16:37:52Z
dc.date.available2011-01-25T16:37:52Z
dc.date.issued2011-02-01
dc.date.submitted2011-01-21
dc.identifier.citationTrop Med Int Health 2011;16(2):205-13en
dc.identifier.issn1365-3156
dc.identifier.pmid21087376
dc.identifier.doi10.1111/j.1365-3156.2010.02689.x
dc.identifier.urihttp://hdl.handle.net/10144/120329
dc.description.abstractObjectives  To report immunovirological outcomes and resistance patterns in adults treated with triple combination antiretroviral therapy (cART) for 4 years in an HIV programme of Phnom Penh, Cambodia. Methods  It is a longitudinal study and cross-sectional evaluation of adults receiving cART for 4 years. CD4 cell counts and HIV-1 RNA were quantified, and resistance patterns were determined. Drug-related toxicity was assessed by clinicians and through laboratory testing. Results  After 4 years of cART start, the cumulative probability of retention in care was 0.80 and survival among patients not lost to follow-up was 0.85. A total of 349 patients (98% of eligible) participated in the cross-sectional evaluation. Ninety per cent were receiving first-line therapy, 29% stavudine- and 58% zidovudine-containing regimens (compared with 94% and 3% at cART initiation). Ninety-three per cent of patients were clinically asymptomatic, and severe lipodystrophy and dyslipidemia were diagnosed in 7.2% and 4.0%, respectively. Good treatment adherence was reported by 83% of patients. Median CD4 T-cell count was 410 cells/μl [IQR 290-511], and 90% of patients had >200 cells/μl. Only 15 (4%) patients had detectable HIV viral load (eight had <200 CD4 cells/μl), five had thymidine analogue mutations, and nine were resistant to two drug classes. In an intention-to-treat analysis, 26.1% (95% CI 22.0-30.5) of patients had failed first-line therapy. Conclusions  In this Cambodian cohort of adults who started cART at an advanced stage of HIV disease, we observed good clinical and immunovirological outcomes and self-reported treatment adherence at 4 years of therapy.
dc.languageENG
dc.language.isoenen
dc.relation.urlhttp://onlinelibrary.wiley.com/doi/10.1111/j.1365-3156.2010.02689.x/abstracten
dc.rightsArchived on this site with the kind permission of Wiley-Blackwell, [url]http://www.blackwell-synergy.com/loi/tmi[/url]en
dc.subject.meshHIV/AIDSen
dc.subject.meshAntiretroviral Therapyen
dc.subject.meshCambodiaen
dc.subject.meshDrug Resistanceen
dc.subject.meshTreatment Outcomeen
dc.titleImmunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodiaen
dc.typeArticleen
dc.contributor.departmentEpicentre, Paris, France; Medecins Sans Frontieres, Phnom Penh, Cambodia; HIV⁄Hepatitis Laboratory, Pasteur Institute, Phnom Penh, Cambodia; Khmero-Sovietic Friendship Hospital, Phnom Penh, Cambodia; Medecins Sans Frontieres, Paris, Franceen
dc.identifier.journalTropical Medicine & International Health : TM & IHen
refterms.dateFOA2019-03-04T08:37:44Z
html.description.abstractObjectives  To report immunovirological outcomes and resistance patterns in adults treated with triple combination antiretroviral therapy (cART) for 4 years in an HIV programme of Phnom Penh, Cambodia. Methods  It is a longitudinal study and cross-sectional evaluation of adults receiving cART for 4 years. CD4 cell counts and HIV-1 RNA were quantified, and resistance patterns were determined. Drug-related toxicity was assessed by clinicians and through laboratory testing. Results  After 4 years of cART start, the cumulative probability of retention in care was 0.80 and survival among patients not lost to follow-up was 0.85. A total of 349 patients (98% of eligible) participated in the cross-sectional evaluation. Ninety per cent were receiving first-line therapy, 29% stavudine- and 58% zidovudine-containing regimens (compared with 94% and 3% at cART initiation). Ninety-three per cent of patients were clinically asymptomatic, and severe lipodystrophy and dyslipidemia were diagnosed in 7.2% and 4.0%, respectively. Good treatment adherence was reported by 83% of patients. Median CD4 T-cell count was 410 cells/μl [IQR 290-511], and 90% of patients had >200 cells/μl. Only 15 (4%) patients had detectable HIV viral load (eight had <200 CD4 cells/μl), five had thymidine analogue mutations, and nine were resistant to two drug classes. In an intention-to-treat analysis, 26.1% (95% CI 22.0-30.5) of patients had failed first-line therapy. Conclusions  In this Cambodian cohort of adults who started cART at an advanced stage of HIV disease, we observed good clinical and immunovirological outcomes and self-reported treatment adherence at 4 years of therapy.


Files in this item

Thumbnail
Name:
101119_Pujades_ART-Cambodia-ou ...
Size:
160.2Kb
Format:
PDF
Description:
Main article

This item appears in the following Collection(s)

Show simple item record